Non-viral delivery of genome-editing nucleases for gene therapy

Gene Therapy

Volumn 24, Issue 3, 2017, Pages 144-150

  Wang, M ^a,b   Glass, Z A ^a   Xu, Q ^a  

^a Tufts University   (United States)

^b INSTITUTE OF CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAS9 PROTEIN; CELL PENETRATING PEPTIDE; NANOPARTICLE; NUCLEASE; RIBONUCLEOPROTEIN; SGRNA RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CAS9 ENDONUCLEASE STREPTOCOCCUS PYOGENES; ENDONUCLEASE;

ELECTROPORATION; GENE EDITING; GENE THERAPY; HUMAN; HYDRODYNAMICS; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; CRISPR CAS SYSTEM; GENE TRANSFER; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; BACTERIAL PROTEINS; CRISPR-CAS SYSTEMS; ENDONUCLEASES; GENE EDITING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; NANOPARTICLES;

EID: 85001121741     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2016.72     Document Type: Review

References (61)

1. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015; 21: 121-131.
2. Carroll D. Genome engineering with targetable nucleases. Annu Rev Biochem 2014; 83: 409-439.
3. Gersbach CA. Genome engineering: the next genomic revolution. Nat Meth 2014; 11: 1009-1011.
4. Maggio I, Gonçalves MAFV. Genome editing at the crossroads of delivery, specificity, and fidelity. Trends Biotech 2015; 33: 280-291.
5. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotech 2013; 31: 397-405.
6. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-910.
7. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S et al. Multiplex genome-edited T-cell manufacturing platform for 'Off-the-Shelf' adoptive T-cell immunotherapies. Cancer Res 2015; 75: 3853-3864.
8. Kirchner M, Schneider S. CRISPR-Cas: from the bacterial adaptive immune system to a versatile tool for genome engineering. Angew Chem Int Ed 2015; 54: 13508-13514.
9. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346: 6213.
10. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014; 343: 84-87.
11. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-823.
12. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821.
13. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-826.
14. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 15: 1262-1278.
15. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Meth 2013; 10: 957-963.
16. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotech 2014; 32: 347-355.
17. Jasin M, Haber JE. The democratization of gene editing: insights from site-specific cleavage and double-strand break repair. DNA Repair 2016; 44: 6-16.
18. Keener AB. Delivering the goods: scientists seek a way to make CRISPR-Cas gene editing more targeted. Nat Med 2015; 21: 1239-1241.
19. Nelson CE, Gersbach CA. Engineering delivery vehicles for genome editing. Annu Rev Chem Biomol Eng 2016; 7: 637-662.
20. Gori JL, Hsu PD, Maeder ML, Shen S, Welstead GG, Bumcrot D. Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy. Hum Gene Ther 2015; 26: 443-451.
21. Li L, He Z-Y, Wei X-W, Gao G-P, Wei Y-Q. Challenges in CRISPR/Cas9 delivery: potential roles of nonviral vectors. Hum Gene Ther 2015; 26: 452-462.
22. LaFountaine JS, Fathe K, Smyth HDC. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int J Pharm 2015; 494(1): 180-194.
23. Ain QU, Chung JY, Kim Y-H. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J Control Release 2015; 205: 120-127.
24. Holkers M, Cathomen T, Gonçalves MAFV. Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. Methods 2014; 69: 179-187.
25. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475: 217-221.
26. Choi JG, Dang Y, Abraham S, Ma H, Zhang J, Guo H et al. Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther 2016; 23: 627-633.
27. Cai Y, Bak RO, Mikkelsen JG. Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. eLife 2014; 3: e01911.
28. Chen X, Goncalves MAFV. Engineered viruses as genome editing devices. Mol Ther 2016; 44: 447-457.
29. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520: 186-191.
30. Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotech 2015; 208: 44-53.
31. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotech 2015; 33: 73-80.
32. Kim S, Kim D, Cho SW, Kim J, Kim J-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 2014; 24: 1012-1019.
33. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 2015; 112: 10437-10442.
34. Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther 2007; 15: 2063-2069.
35. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotech 2014; 32(6): 551-553.
36. Bijarnia S, Puri RD, Ruel J, Gray GF, Jenkinson L, Verma IC. Tyrosinemia type I-diagnostic issues and prenatal diagnosis. Indian J Pediatr 2006; 73(2): 163-165.
37. Nakase I, Akita H, Kogure K, Gräslund A, Langel Ü, Harashima H et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating pep-tides. Acc Chem Res 2012; 45: 1132-1139.
38. Ru R, Yao Y, Yu S, Yin B, Xu W, Zhao S et al. Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Cell Regen 2013; 2: 5.
39. Liu J, Gaj T, Patterson JT, Sirk SJ, Barbas Iii CF. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One 2014; 9: e85755.
40. Ramakrishna S, Kwaku Dad A-B, Beloor J, Gopalappa R, Lee S-K, Kim H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 2014; 24: 1020-1027.
41. Rizzuti M, Nizzardo M, Zanetta C, Ramirez A, Corti S. Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov Today 2015; 20: 76-85.
42. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014; 15: 541-555.
43. Gu Z, Biswas A, Zhao M, Tang Y. Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev 2011; 40: 3638-3655.
44. Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotech 2007; 2: 751-760.
45. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
46. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005; 4: 298-306.
47. Urnov FD, Miller JC, Lee Y-L, Beausejour CM, Rock JM, Augustus S et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-651.
48. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18: 947-954.
49. Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest 2015; 125: 425-436.
50. Mahiny AJ, Dewerth A, Mays LE, Alkhaled M, Mothes B, Malaeksefat E et al. In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat Biotech 2015; 33: 584-586.
51. Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci USA 2016; 113: 2868-2873.
52. Wang M, Alberti K, Varone A, Pouli D, Georgakoudi I, Xu Q. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles. Adv Health Mater 2014; 3: 1398-1403.
53. Altinoglu S, Wang M, Xu Q. Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications. Nano-medicine 2015; 10: 643-657.
54. Wang M, Sun S, Neufeld CI, Perez-Ramirez B, Xu Q. Reactive oxygen species-responsive protein modification and its intracellular delivery for targeted cancer therapy. Angew Chem Int Ed 2014; 53: 13444-13448.
55. Wang M, Alberti K, Sun S, Arellano C, Xu Q. Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy. Angew Chem Int Ed 2014; 53: 2893-2898.
56. Wang M, Sun S, Alberti K, Xu Q. A combinatorial library of unsaturated lipidoids for efficient intracellular gene delivery. ACS Synth Biol 2012; 1: 403-407.
57. Sun S, Wang M, Knupp S, Soto-Feliciano Y, Hu X, Kaplan D et al. Combinatorial library of lipidoids for in vitro DNA delivery. Bioconjugate Chem 2012; 23: 135-140.
58. Sun S, Wang M, Alberti K, Choy A, Xu Q. DOPE facilitates quaternized lipidoids (QLDs) for in vitro DNA delivery. Nanomedicine 2013; 9: 849-854.
59. Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed 2015; 54: 12029-12033.
60. D'Astolfo Diego S, Pagliero Romina J, Pras A, Karthaus Wouter R, Clevers H, Prasad V et al. Efficient intracellular delivery of native proteins. Cell 2015; 161: 674-690.
61. Yin H, Song C-Q, Dorkin JR, Zhu LJ, Li Y, Wu Q et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotech 2016; 34: 328-333.